Investors

Press Releases

Press Releases

June 25, 2024
Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile
– AK006 achieved serum concentrations consistent with levels demonstrating inhibitory activity in preclinical experiments – – Skin biopsies from subjects treated with AK006 show high receptor occupancy – – AK006 was well-tolerated with a favorable safety profile – SAN CARLOS, Calif.
February 12, 2024
Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition
–  Data provide insights on the signaling pathways involved with AK006 mast cell inhibition – – AK006 has a distinct mechanism of action that leads to broad inhibitory effects on mast cells – SAN CARLOS, Calif. , Feb. 12, 2024 (GLOBE NEWSWIRE) -- Allakos Inc.
January 16, 2024
Allakos Announces a Restructuring to Focus on Development of AK006
Existing cash to fund planned ongoing operations into mid-2026 AK006 is being tested in a comprehensive Phase 1 clinical program, including: ongoing single and multiple ascending dose trial in healthy volunteers a randomized, double-blind, placebo-controlled trial in patients with CSU a
Displaying 1 - 10 of 11


(Common Stock)


December 11, 2024 12:04 AM EST

Minimum 15 minutes delayed. Source: LSEG